High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1829-1835

  Tidehag, Viktor ^a   Hammarsten, Peter ^a   Egevad, Lars ^b   Granfors, Torvald ^c   Stattin, Pär ^a   Leanderson, Tomas ^d   Wikström, Pernilla ^a   Josefsson, Andreas ^a   Hägglöf, Christina ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Prognostic marker; Prostate cancer; S100A9; Watchful waiting

Indexed keywords

ANDROGEN RECEPTOR; CALGRANULIN B; HYALURONIC ACID; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; DENSITY; EVENT FREE SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STROMA; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; WATCHFUL WAITING;

PROGNOSTIC MARKER; PROSTATE CANCER; S100A9; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; CALGRANULIN B; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; STROMAL CELLS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; WATCHFUL WAITING;

EID: 84901761552     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.278     Document Type: Article

References (38)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. J.E. Johansson, O. Andren, S.O. Andersson, P.W. Dickman, L. Holmberg, and A. Magnuson et al. Natural history of early, localized prostate cancer JAMA 291 22 2004 2713 2719
3. J.E. Damber, and G. Aus Prostate cancer Lancet 371 9625 2008 1710 1721
4. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1 1974 58 64
5. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Prognostic value of the Gleason score in prostate cancer BJU Int 89 6 2002 538 542
6. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
7. C. Hägglöf, and A. Bergh The stroma - a key regulator in prostate function and malignancy Cancers 4 2 2012 531 548
8. I.F. Lissbrant, P. Stattin, P. Wikstrom, J.E. Damber, L. Egevad, and A. Bergh Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival Int J Oncol 17 3 2000 445 451
9. P. Hammarsten, A. Karalija, A. Josefsson, S.H. Rudolfsson, P. Wikstrom, and L. Egevad et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients Clin Cancer Res 16 4 2010 1245 1255
10. P. Hammarsten, M. Cipriano, A. Josefsson, P. Stattin, L. Egevad, and T. Granfors et al. Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression PLoS One 7 10 2012 e47994
11. S. Davidsson, A.L. Ohlson, S.O. Andersson, K. Fall, A. Meisner, and M. Fiorentino et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer Mod Pathol 26 3 2013 448 455
12. A. Flammiger, F. Bayer, A. Cirugeda-Kuhnert, H. Huland, P. Tennstedt, and R. Simon et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer APMIS 120 11 2012 901 908
13. S. Halin, S.H. Rudolfsson, N. Van Rooijen, and A. Bergh Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model Neoplasia 11 2 2009 177 186
14. E. Kallberg, T. Vogl, D. Liberg, A. Olsson, P. Bjork, and P. Wikstrom et al. S100A9 interaction with TLR4 promotes tumor growth PLoS One 7 3 2012 e34207
15. I. Marenholz, C.W. Heizmann, and G. Fritz S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) Biochem Biophys Res Commun 322 4 2004 1111 1122
16. P. Bjork, A. Bjork, T. Vogl, M. Stenstrom, D. Liberg, and A. Olsson et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides PLoS Biol 7 4 2009 e97
17. T. Vogl, K. Tenbrock, S. Ludwig, N. Leukert, C. Ehrhardt, and M.A. van Zoelen et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock Nat Med 13 9 2007 1042 1049
18. D. Foell, H. Wittkowski, T. Vogl, and J. Roth S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules J Leukoc Biol 81 1 2007 28 37
19. M.M. McCormick, F. Rahimi, Y.V. Bobryshev, K. Gaus, H. Zreiqat, and H. Cai et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis J Biol Chem 280 50 2005 41521 41529
20. A. Hermani, J. Hess, B. De Servi, S. Medunjanin, R. Grobholz, and L. Trojan et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer Clin Cancer Res 11 14 2005 5146 5152
21. C. Gebhardt, J. Nemeth, P. Angel, and J. Hess S100A8 and S100A9 in inflammation and cancer Biochem Pharmacol 72 11 2006 1622 1631
22. 2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray Oncogene 23 6 2004 1291 1299
23. J.P. Kong, F. Ding, C.N. Zhou, X.Q. Wang, X.P. Miao, and M. Wu et al. Loss of myeloid-related proteins 8 and myeloid-related proteins 14 expression in human esophageal squamous cell carcinoma correlates with poor differentiation World J Gastroenterol 10 8 2004 1093 1097
24. S.L. Dalrymple, R.E. Becker, and J.T. Isaacs The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts Prostate 67 7 2007 790 797
25. J.T. Isaacs, R. Pili, D.Z. Qian, S.L. Dalrymple, J.B. Garrison, and N. Kyprianou et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer Prostate 66 16 2006 1768 1778
26. K. Jennbacken, K. Welen, A. Olsson, B. Axelsson, M. Torngren, and J.E. Damber et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050) Prostate 72 8 2012 913 924
27. P. Wikstrom, J. Marusic, P. Stattin, and A. Bergh Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients Prostate 69 8 2009 799 809
28. C. Hagglof, P. Hammarsten, A. Josefsson, P. Stattin, J. Paulsson, and A. Bergh et al. Stromal PDGFR-beta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival PLoS One 5 5 2010 e10747
29. A. Josefsson, H. Adamo, P. Hammarsten, T. Granfors, P. Stattin, and L. Egevad et al. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome Am J Pathol 179 4 2011 1961 1968
30. J. Roth, T. Vogl, C. Sorg, and C. Sunderkotter Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules Trends Immunol 24 4 2003 155 158
31. S. Grebhardt, C. Veltkamp, P. Strobel, and D. Mayer Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer Int J Cancer 131 12 2012 2785 2794
32. S. Halin, P. Hammarsten, H. Adamo, P. Wikstrom, and A. Bergh Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer Expert Opin Med Diagn 5 1 2011 37 47
33. J. Massague TGFbeta in Cancer Cell 134 2 2008 215 230
34. P. Cheng, C.A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, and M.M. Bui et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein J Exp Med 205 10 2008 2235 2249
35. G. Di Lorenzo, C. Buonerba, and P.W. Kantoff Immunotherapy for the treatment of prostate cancer Nat Rev Clin Oncol 8 9 2011 551 561
36. A. Olsson, A. Bjork, J. Vallon-Christersson, J.T. Isaacs, and T. Leanderson Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors Mol Cancer 9 2010 107
37. R. Pili, M. Haggman, W.M. Stadler, J.R. Gingrich, V.J. Assikis, and A. Bjork et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 29 30 2011 4022 4028
38. O. Bratt, M. Haggman, G. Ahlgren, O. Nordle, A. Bjork, and J.E. Damber Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer Br J Cancer 101 8 2009 1233 1240